The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...
In a report released today, Allison Bratzel from Piper Sandler initiated coverage with a Buy rating on Replimune Group (REPL – Research Report) and a price target of $44.00. The company’s shares ...
We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
NEW YORK, Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the ...
Good morning and welcome to the Replimune Fiscal Year Fourth Quarter 2025 Financial Results and Corporate Update Conference Call. Currently, all participants are in listen-only mode. This call is ...
In a report released on January 5, Kaveri Pohlman from BTIG maintained a Buy rating on Replimune Group (REPL – Research Report), with a price target of $13.00. The company’s shares closed last Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results